Teva Announces Update On Fremanezumab Clinical Development For Use In Episodic Cluster Headache
April 23 (Reuters) - Teva Pharmaceutical Industries Ltd
Latest Developments forTeva Pharmaceutical Industries Ltd
- FDA Says Teva Expanding Its Voluntary Recall To Include 7 Additional Lots Of Losartan Potassium Tablets
- FDA Says Teva Pharmaceuticals USA Expands Voluntary Nationwide Recall Of Losartan Potassium
- Teva Announces Launch Of Generic Version Of Ranexa Extended-Release Tablets In U.S.
- Teva Announces Launch Of A Generic Version Of Vesicare Tablets In U.S.
Latest Key Developments inPharmaceuticals
- Verrica Pharmaceuticals Says Board Appointed Craig Ballaron To Serve As Director Of Co
- Amgen Sues HHS On Rule Requiring Drug Prices In TV Ads
- Theravance Biopharma and Mylan Expand YUPELRI Development and Commercialization Agreement to Include China and Adjacent Territories
- Canopy Growth, Acreage Holdings Remind Shareholders To Vote For Canopy Growth's Plan To Acquire Acreage